NOVO.B.DK

281.75

+4.93%↑

GMAB.DK

1,615.5

+0.09%↑

COLO.B.DK

384.1

-1.13%↓

ZEAL.DK

285.1

+1.57%↑

AMBUB.DK

64.2

-1.46%↓

NOVO.B.DK

281.75

+4.93%↑

GMAB.DK

1,615.5

+0.09%↑

COLO.B.DK

384.1

-1.13%↓

ZEAL.DK

285.1

+1.57%↑

AMBUB.DK

64.2

-1.46%↓

NOVO.B.DK

281.75

+4.93%↑

GMAB.DK

1,615.5

+0.09%↑

COLO.B.DK

384.1

-1.13%↓

ZEAL.DK

285.1

+1.57%↑

AMBUB.DK

64.2

-1.46%↓

NOVO.B.DK

281.75

+4.93%↑

GMAB.DK

1,615.5

+0.09%↑

COLO.B.DK

384.1

-1.13%↓

ZEAL.DK

285.1

+1.57%↑

AMBUB.DK

64.2

-1.46%↓

NOVO.B.DK

281.75

+4.93%↑

GMAB.DK

1,615.5

+0.09%↑

COLO.B.DK

384.1

-1.13%↓

ZEAL.DK

285.1

+1.57%↑

AMBUB.DK

64.2

-1.46%↓

Search

H Lundbeck A-S

Abierto

44.46 3.4

Resumen

Variación precio

24h

Actual

Mínimo

42.8

Máximo

44.6

Métricas clave

By Trading Economics

Ingresos

1.7B

1.7B

Ventas

1.2B

7B

P/B

Media del Sector

11.535

49.888

BPA

1.671

Rentabilidad por dividendo

2.65

Margen de beneficios

23.601

Empleados

5,000

EBITDA

598M

2.4B

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

2.65%

2.38%

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

833M

43B

Apertura anterior

41.06

Cierre anterior

44.46

H Lundbeck A-S Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

9 jun 2026, 23:49 UTC

Charlas de Mercado

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

9 jun 2026, 23:45 UTC

Adquisiciones, fusiones, absorciones

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

9 jun 2026, 23:44 UTC

Adquisiciones, fusiones, absorciones

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

9 jun 2026, 23:44 UTC

Adquisiciones, fusiones, absorciones

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

9 jun 2026, 23:43 UTC

Adquisiciones, fusiones, absorciones

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

9 jun 2026, 23:35 UTC

Charlas de Mercado

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

9 jun 2026, 22:06 UTC

Adquisiciones, fusiones, absorciones

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

9 jun 2026, 22:05 UTC

Adquisiciones, fusiones, absorciones

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

9 jun 2026, 22:05 UTC

Adquisiciones, fusiones, absorciones

Samsung: Additional Investment Makes It Largest Shareholder in Element

9 jun 2026, 22:05 UTC

Adquisiciones, fusiones, absorciones

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

9 jun 2026, 20:51 UTC

Ganancias

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

9 jun 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

9 jun 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

9 jun 2026, 20:09 UTC

Charlas de Mercado

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

9 jun 2026, 19:36 UTC

Charlas de Mercado

Cattle Climbs as Crude Oil Falls -- Market Talk

9 jun 2026, 19:32 UTC

Charlas de Mercado

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

9 jun 2026, 19:25 UTC

Charlas de Mercado

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

9 jun 2026, 19:00 UTC

Charlas de Mercado

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

9 jun 2026, 18:52 UTC

Adquisiciones, fusiones, absorciones

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

9 jun 2026, 18:47 UTC

Charlas de Mercado

No World Cup Inflation Seen So Far in Mexico -- Market Talk

9 jun 2026, 18:37 UTC

Charlas de Mercado

Canada's Cooling Trade With the U.S. -- Market Talk

9 jun 2026, 18:27 UTC

Charlas de Mercado

Precious Metals Lower as Trump Vows Military Response -- Market Talk

9 jun 2026, 17:35 UTC

Charlas de Mercado

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

9 jun 2026, 17:30 UTC

Charlas de Mercado

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

9 jun 2026, 16:34 UTC

Charlas de Mercado

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

9 jun 2026, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

9 jun 2026, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

9 jun 2026, 16:20 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Health Care Roundup: Market Talk

9 jun 2026, 15:28 UTC

Charlas de Mercado

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

9 jun 2026, 15:25 UTC

Charlas de Mercado

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Comparación entre iguales

Cambio de precio

H Lundbeck A-S previsión

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de H Lundbeck A-S

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat MDD and schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat dementia; Onfi for epilepsy; Sabril for the treatment of refractory complex partial seizures and infantile spasms; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol to treat psychosis. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.
help-icon Live chat